Table 2.
The performance of urine exosomal AMACR and clinical features to predict biopsy results in the training cohort.
| Parameters | Positive and negative | Non-aggressive and csPCa | ||
|---|---|---|---|---|
| AUC (95% CI) |
Univariate p | AUC (95% CI) |
Univariate p | |
| Age | 0.622 (0.536 to 0.703) |
0.008 | 0.631 (0.546 to 0.712) |
0.014 |
| BMI | 0.544 (0.458 to 0.629) |
0.746 | 0.541 (0.454 to 0.625) |
0.211 |
| PSA | 0.645 (0.559 to 0.724) |
0.017 | 0.674 (0.589 to 0.751) |
0.006 |
| f/t PSA | 0.689 (0.588 to 0.779) |
0.002 | 0.645 (0.542 to 0.740) |
0.020 |
| PSAD | 0.692 (0.608 to 0.767) |
<0.001 | 0.700 (0.616 to 0.774) |
<0.001 |
| AMACR | 0.832 (0.759 to 0.890) |
<0.001 | 0.780 (0.701 to 0.846) |
<0.001 |
AUC, area under the curve; PSA, prostate-specific antigen; PSAD, prostate-specific antigen density; f/t PSA, free prostate-specific antigen/total prostate-specific antigen; csPCa, clinically significant prostate cancer.